- Home
- KZIA vs SXTP Comparison
KZIA vs SXTP Comparison
Compare KZIA & SXTP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KZIA
- SXTP
- Stock Information
- Founded
- KZIA 1994
- SXTP 2010
- Country
- KZIA Australia
- SXTP United States
- Employees
- KZIA N/A
- SXTP N/A
- Industry
- KZIA Biotechnology: Pharmaceutical Preparations
- SXTP Biotechnology: Pharmaceutical Preparations
- Sector
- KZIA Health Care
- SXTP Health Care
- Exchange
- KZIA Nasdaq
- SXTP Nasdaq
- Market Cap
- KZIA 5.1M
- SXTP 4.3M
- IPO Year
- KZIA 1999
- SXTP 2023
- Fundamental
- Price
- KZIA $6.10
- SXTP $2.32
- Analyst Decision
- KZIA Strong Buy
- SXTP Buy
- Analyst Count
- KZIA 2
- SXTP 2
- Target Price
- KZIA $57.50
- SXTP $7.00
- AVG Volume (30 Days)
- KZIA 2.6M
- SXTP 324.9K
- Earning Date
- KZIA 07-07-2025
- SXTP 08-13-2025
- Dividend Yield
- KZIA N/A
- SXTP N/A
- EPS Growth
- KZIA N/A
- SXTP N/A
- EPS
- KZIA N/A
- SXTP N/A
- Revenue
- KZIA $1,549,158.00
- SXTP $802,323.00
- Revenue This Year
- KZIA N/A
- SXTP $95.50
- Revenue Next Year
- KZIA N/A
- SXTP $80.78
- P/E Ratio
- KZIA N/A
- SXTP N/A
- Revenue Growth
- KZIA 248983.08
- SXTP 118.37
- 52 Week Low
- KZIA $2.86
- SXTP $1.41
- 52 Week High
- KZIA $79.00
- SXTP $35.99
- Technical
- Relative Strength Index (RSI)
- KZIA 50.96
- SXTP 50.64
- Support Level
- KZIA $5.83
- SXTP $1.91
- Resistance Level
- KZIA $9.60
- SXTP $2.55
- Average True Range (ATR)
- KZIA 1.19
- SXTP 0.24
- MACD
- KZIA -0.29
- SXTP -0.00
- Stochastic Oscillator
- KZIA 18.39
- SXTP 46.09
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.
About SXTP 60 Degrees Pharmaceuticals Inc.
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline products under development cover development programs for COVID-19, fungal, tick-borne, and other viral diseases.